Literature DB >> 11161398

Prediction of relapse after lymph node dissection for germ cell tumours: can salvage chemotherapy be avoided?

D M Berney1, J Shamash, W F Hendry, A Arora, S Jordan, R T Oliver.   

Abstract

Salvage chemotherapy has been used by some oncology centres for patients with residual malignant or immature elements in retroperitoneal lymph node dissections removed for metastatic non-seminomatous germ cell tumours. However, surveillance of these patients shows that many are cured by surgery alone. 118 retroperitoneal lymph node dissections for metastatic non-seminomatous germ cell tumours were reviewed and the morphology seen within them was quantified. 28 of these had immature or malignant elements and had been treated by surveillance before administration of further chemotherapy. The proliferation rate in these cases was assessed by immunochemistry. The proliferation index and the amount of embryonal carcinoma (EC) were both predictors of recurrence and therefore the need for further chemotherapy. Patients with greater than 25% of EC had an 84% chance of relapse and those with a Ki-67 index of greater than 50% had a 71% chance of relapse. The two tests had a positive predictive value of 83% and 71%, respectively. Patients with such a high risk of recurrence could be considered for post-operative adjuvant therapy at this point whilst others would be suitable for a watchful waiting approach.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161398      PMCID: PMC2363736          DOI: 10.1054/bjoc.2000.1613

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.

Authors:  A Heidenreich; N S Schenkmann; I A Sesterhenn; F K Mostofi; W F McCarthy; B Heidenreich; J W Moul
Journal:  J Urol       Date:  1997-08       Impact factor: 7.450

2.  A single-centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer.

Authors:  R Ravi; R T Oliver; J Ong; D F Badenoch; C G Fowler; A M Paris; W F Hendry
Journal:  Br J Urol       Date:  1997-10

3.  Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer?

Authors:  H W Herr
Journal:  Br J Urol       Date:  1997-10

4.  Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer.

Authors:  P Stattin; J E Damber; L Karlberg; A Bergh
Journal:  J Urol       Date:  1997-01       Impact factor: 7.450

Review 5.  Cellular interactions in prostate cancer.

Authors:  C Lee
Journal:  Br J Urol       Date:  1997-03

6.  MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis.

Authors:  P Albers; E Bierhoff; D Neu; R Fimmers; N Wernert; S C Müller
Journal:  Cancer       Date:  1997-05-01       Impact factor: 6.860

7.  Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.

Authors:  E B Fernandez; I A Sesterhenn; W F McCarthy; F K Mostofi; J W Moul
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450

8.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.

Authors:  E W Steyerberg; H J Keizer; S D Fosså; D T Sleijfer; G C Toner; H Schraffordt Koops; P F Mulders; J E Messemer; K Ney; J P Donohue
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

9.  Unusual neoplasms detected in testis cancer patients undergoing post-chemotherapy retroperitoneal lymphadenectomy.

Authors:  J S Little; R S Foster; T M Ulbright; J P Donohue
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450

10.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

Authors:  P J Loehrer; R Gonin; C R Nichols; T Weathers; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

View more
  2 in total

Review 1.  Testis cancer.

Authors:  Omar Khan; Andrew Protheroe
Journal:  Postgrad Med J       Date:  2007-10       Impact factor: 2.401

2.  DNA topoisomerase I and II expression in drug resistant germ cell tumours.

Authors:  D M Berney; J Shamash; J Gaffney; S Jordan; R T D Oliver
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.